#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bladder cancer Osteochondrodysplasia Pericarditis Tuberous sclerosis complex Follicular lymphoma Neuropathic arthropathy Netherton's syndrome Penile squamous cell carcinoma Progressive multifocal leukoencephalopathy Neonatal alloimmune thrombocytopenia Leukaemia Progressive supranuclear palsy Fibrous dysplasia of bone Von Hippel-Lindau disease Neuroblastoma More trials…

    Learn about Rare Diseases

    Synovial sarcoma metastatic – Diagnostics Short-bowel syndrome – Diagnostics Fabry’s disease – Diagnostics Alagille syndrome – Basic Information Tuberous sclerosis complex – Basic Information Antisynthetase syndrome – Treatment Gaucher’s disease type I – Treatment Mucopolysaccharidosis I – Treatment Piriformis syndrome Gastrointestinal stromal tumour More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tazobactam ICOTROKINRA Dobutamine Citicoline Sodium COBALAMIN Cholesterol Caplacizumab Cldn6 Car-T Tenofovir Disoproxil Tradipitant Prucalopride Fludeoxyglucose (18F) SODIUM DIHYDROGEN PHOSPHATE Phenol Setanaxib PHENTOLAMINE MESILATE Axicabtagene Ciloleucel Cenerimod Bio89-100 Dinutuximab Beta More therapies…

    Learn about Your Condition

    Small cell lung cancer Urticaria chronic Stargardt's disease Perineal injury Netherton's syndrome Medulloblastoma Hepatoblastoma Primary hyperoxaluria Alveolar rhabdomyosarcoma Acute cardiac event Neutropenia Hypoalbuminaemia Leiomyosarcoma recurrent Pulmonary alveolar haemorrhage Low cardiac output syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Radiotherapy with Cetuximab and Xevinapant for Patients with Advanced Head and Neck Cancer Unfit for High-Dose Cisplatin

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • Xevinapant
    • Cetuximab
    France

  • Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Olaparib
    • Pembrolizumab
    France Germany Italy Latvia Poland Romania +2

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Antiemetics And Antinauseants
    • Antipsychotics
    • Corticosteroids, Plain
    Austria Belgium Czechia France Germany Greece +5

  • Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Patritumab Deruxtecan
    Austria Belgium France Germany Italy The Netherlands +4

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala
    • Mps-102
    • Mps-103
    Belgium France Germany

  • Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Hormone receptor positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Fulvestrant
    • Olaparib
    • Durvalumab
    Belgium France Spain

  • Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma – a rare bone cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • 1,3-BUTYLENE GLYCOL
    • Acetylcysteine
    • Cinchocaine Hydrochloride
    France Germany Ireland Italy The Netherlands Spain

  • Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    France Germany Italy Norway Spain Sweden

  • Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • HER2 negative breast cancer
    • Hormone receptor negative HER2 positive breast cancer
    Investigated Drugs:
    • Fluoroestradiol F-18
    France

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell cancer of the renal pelvis and ureter
    • Transitional cell carcinoma urethra
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Vinflunine
    • Docetaxel
    • Paclitaxel
    Belgium France Germany Greece Ireland Italy +2
Previous Page
1 … 22 23 24 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!